SONN — Sonnet Biotherapeutics Holdings Share News
0.000.00%
Last trade - 00:00- $26.33m
- $26.01m
- $0.02m
Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended in March - Earnings Summary
Brief: Sonnet Biotherapeutics Posts Qtrly Net Loss Per Share Of $0.34
Sonnet Biotherapeutics Holdings Inc expected to post a loss of 49 cents a share - Earnings Preview
Brief: Sonnet Biotherapeutics - On March 23, Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
Sonnet Biotherapeutics Holdings Inc expected to post a loss of $1.10 a share - Earnings Preview
Brief: Sonnet Biotherapeutics Holdings Inc Files For Common Stock Offering - SEC Filing
Brief: Sonnet Biotherapeutics Announces Pharmacokinetic and Pharmacodynamic Data In A Phase 1 Dose-Escalation Trial Of Son-1010
U.S. STOCKS ON THE MOVE-Abercrombie & Fitch, Lululemon Athletica, Oracle
Sonnet BioTherapeutics rises on pact with Roche to test lead cancer therapy
Brief: Sonnet Biotherapeutics Announces A Collaboration With Roche For The Clinical Evaluation Of Son-1010 With Atezolizumab In Ovarian Cancer
Brief: Sonnet Biotherapeutics Announces Interim Data In Two Phase 1 Dose-Escalation Trials Of Son-1010
U.S. STOCKS ON THE MOVE-Insperity, Nikola, First Solar
U.S. STOCKS ON THE MOVE-Natgas, Wynn Resorts, Ascendis Pharma
Sonnet Bio up on agreement with J&J's Janssen for cancer therapies
Brief: Sonnet Biotherapeutics Holdings Inc Announces A Collaboration Agreement With Janssen Biotech - Filing
Brief: Sonnet Biotherapeutics Says Common Stock Will Begin Trading On Reverse Stock Split-Adjusted Basis When Market Opens On September 19
U.S. STOCKS ON THE MOVE-Waterdrop, Gogo, Roblox
U.S. STOCKS ON THE MOVE-Core & Main, JanOne, Belite Bio
U.S. STOCKS ON THE MOVE-Syros, Huntsman, Sonnet BioTherapeutics